Daily Endocrinology Research Analysis
Analyzed 76 papers and selected 3 impactful papers.
Summary
Top endocrinology papers today span mechanistic immunometabolism, kidney-cardiometabolic therapeutics, and steatohepatitis drug development. A Cell Reports study identifies Ets1 as a stimulus-specific Erk effector driving anti-inflammatory macrophage polarization and ameliorating insulin resistance; a meta-analysis suggests post-AKI exposure to SGLT2 inhibitors/GLP-1 RAs may improve outcomes; and a large network meta-analysis benchmarks phase 2–3 MASH therapies, favoring metabolic mechanisms.
Research Themes
- Stimulus-specific Erk signaling in immunometabolism
- Cardio-renal outcomes with SGLT2i/GLP-1 RA after AKI
- Cross-class benchmarking of MASH therapeutics
Selected Articles
1. Ets1-dependent Mek-Erk signaling drives adipose tissue macrophage anti-inflammatory polarization to ameliorates insulin resistance.
This mechanistic study reveals Ets1 as a stimulus-specific Erk effector activated by IL-4 (via T38 phosphorylation) that upregulates Irf4 and drives anti-inflammatory macrophage polarization, improving adipose inflammation and metabolic phenotypes. Myeloid Ets1 deletion worsened inflammation and insulin resistance, delineating an Erk pathway branch that differentiates outputs by upstream cues.
Impact: It uncovers a discrete Erk→Ets1→IRF4 axis that explains paradoxical effects of MEK/ERK modulation and pinpoints a selective node for immunometabolic intervention.
Clinical Implications: Therapeutic strategies should avoid indiscriminate MEK/ERK blockade that may blunt beneficial IL-4/Ets1 signaling; instead, targeting Ets1 activation or its chromatin program could enhance anti-inflammatory macrophage functions to treat insulin resistance.
Key Findings
- Ets1 is selectively activated by IL-4 via Thr38 phosphorylation despite broad Erk activation by multiple stimuli.
- Myeloid-specific Ets1 knockout aggravated adipose inflammation and metabolic dysfunction in physiological and obese states.
- Ets1 upregulates Irf4 through transcriptional control and chromatin remodeling to drive anti-inflammatory macrophage polarization.
- Erk signaling bifurcates to distinct downstream effectors depending on upstream cues, with Ets1 inactive under pro-inflammatory stimuli.
Methodological Strengths
- In vivo myeloid-specific knockout with phenotyping under physiological and obese conditions
- Mechanistic dissection of Ets1 activation (T38 phosphorylation), transcriptional regulation, and chromatin remodeling
Limitations
- Findings are preclinical and require validation in human macrophages and adipose tissue
- Drugability and safety of targeting Ets1 or its pathway remain untested
Future Directions: Validate Ets1-IRF4 axis in human adipose macrophages across metabolic phenotypes; develop selective modulators that enhance IL-4/Ets1 signaling without global MEK/ERK inhibition; test efficacy in diet-induced and genetic insulin resistance models.
Clinical observations reveal that Mek-Erk inhibitors exert paradoxical immunoregulatory effects on macrophages, yet the mechanisms governing the pathway's specific immunoregulatory outputs remain elusive. Here, we identify Ets1 as a discriminative effector that couples Mek-Erk signaling specifically to anti-inflammatory polarization. We show that while various stimuli activate Erk, only the anti-inflammatory IL-4 activates the transcriptional activity of Ets1 in a Thr38 (T38) phosphorylation-dependent manner. Functionally, myeloid-specific Ets1 knockout mice exhibited exacerbated adipose inflammation and metabolic dysfunction under both physiological and obesity conditions. Mechanistically, Ets1 raises Irf4 expression level via both transcriptional regulation and chromatin remodeling, thereby inducing macrophage anti-inflammatory polarization. Taken together, we demonstrate that Ets1 serves as a critical discriminator activated specifically by IL-4 stimulation but remaining inactive under pro-inflammatory conditions. This bifurcated activation enables Erk signaling to differentially engage downstream effectors based on upstream stimuli, thereby directing macrophage functional specialization.
2. SGLT2 Inhibitors and GLP-1 Receptor Agonists After Acute Kidney Injury: A Systematic Review With Meta-Analysis.
Across >430,000 AKI patients, post-AKI exposure to SGLT2 inhibitors or GLP-1 receptor agonists was associated with lower MAKE and mortality, and SGLT2 inhibitors reduced kidney replacement therapy needs. Although derived largely from observational cohorts, consistency across sensitivity analyses supports further randomized testing.
Impact: First synthesis to quantify outcome benefits of cardio-renal-metabolic agents after AKI, informing the risk–benefit calculus of reinitiation and trial design.
Clinical Implications: Clinicians may consider early reassessment for reinitiating SGLT2i/GLP-1 RA after stabilization from AKI, while recognizing observational confounding; prioritize enrollment in trials to define timing and patient selection.
Key Findings
- Post-AKI exposure to SGLT2i/GLP-1 RAs was associated with lower MAKE (OR 0.63, 95% CI 0.46–0.86).
- All-cause mortality was substantially reduced with exposure (OR 0.36, 95% CI 0.21–0.62).
- SGLT2i reduced kidney replacement therapy needs (OR 0.61, 95% CI 0.40–0.93) in evaluated studies.
- Sensitivity analyses limited to SGLT2i data reproduced MAKE and mortality benefits.
Methodological Strengths
- Comprehensive multi-database search including trials registries
- Random-effects meta-analyses with sensitivity analyses
Limitations
- Predominantly observational evidence with potential residual confounding and indication bias
- Heterogeneity in AKI definitions, timing of exposure, and follow-up across studies
Future Directions: Conduct pragmatic randomized trials to define optimal timing and patient selection for reinitiating SGLT2i/GLP-1 RA post-AKI; evaluate safety (e.g., hemodynamics, volume status) and long-term renal/cardiovascular endpoints.
Sodium glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are nephroprotective and their use is recommended for adults with chronic kidney disease (CKD). The role of SGLT2i and GLP-1 RAs in patients with acute kidney injury (AKI) is unknown. This systematic review aimed to estimate the effect of SGLT2i or GLP-1 RAs on clinical outcomes in AKI. We systematically searched Embase, MEDLINE, Scopus, Web of Science Core Collection, and clinical trials registries for observational studies and clinical trials from database inception to July 3, 2025. Included studies evaluated adults (≥ 18 years) with AKI during a hospitalization and compared patients subsequently exposed to either SGLT2i or GLP-1 RAs to a non-exposed control group. Random effects meta-analyses were performed. Six studies related to SGLT2i (five observational, one randomized trial) and one related to GLP-1 RAs (one observational) met eligibility criteria (N = 432,048 patients). SGLT2i/GLP-1 RA exposure was associated with lower odds of major adverse kidney events (MAKE) (OR 0.63, 95% CI 0.46-0.86) and all-cause mortality [odds ratio (OR) 0.36, 95% confidence interval (CI) 0.21-0.62] compared to controls. The odds for kidney replacement therapy were lower with SGLT2i therapy in the three studies where it was evaluated (OR 0.61, 95% CI 0.40-0.93). Sensitivity analyses restricted to SGLT2i data were consistent with the overall findings [MAKE OR 0.63 (95% CI 0.42-0.95); Mortality OR 0.34 (95% CI 0.18, 0.65)]. Exposure to SGLT2i or GLP-1 RAs after AKI, examined primarily in observational studies, was associated with improved clinical outcomes. These findings are promising and warrant evaluation in randomized clinical trials.
3. Comparative efficacy of phase 2-3 therapies for non-cirrhotic metabolic dysfunction-associated steatohepatitis: An updated network meta-analysis.
Across 64 phase 2–3 trials, metabolic/insulin-sensitizing mechanisms (including FGF21 analogs and incretin-based multi-agonists) consistently outperformed placebo on biopsy and MRI-PDFF endpoints in non-cirrhotic MASH. However, 35–70% non-response underscores the need for mechanism-complementary combinations and more durable responses.
Impact: Provides a cross-mechanism benchmark guiding drug selection and rational combination strategies in MASH, a major endocrine-metabolic disease lacking approved therapies in many regions.
Clinical Implications: Prefer metabolic/incretin/FGF21-based agents where trial access permits; counsel patients regarding substantial non-response; design combinations that pair metabolic backbones with anti-inflammatory/antifibrotic complements and employ robust biopsy endpoints.
Key Findings
- Metabolic/insulin-sensitizing therapies achieved the most consistent benefits vs placebo across biopsy and MRI-PDFF endpoints (ORs 2.5–7.1).
- FGF21 analogs and incretin-based multi-agonists ranked among the leading classes in network estimates.
- Absolute non-response remained high (35%–70%) despite favorable relative effects; placebo biopsy responses were 11%–18%.
Methodological Strengths
- Large frequentist network meta-analysis across 64 phase 2–3 RCTs with standardized biopsy and imaging endpoints
- Mechanism-based grouping enabling cross-class comparisons and ranking
Limitations
- Network heterogeneity and placebo anchoring may influence indirect comparisons
- Endpoints are surrogate (biopsy/imaging) with variable trial durations; sponsorship bias possible
Future Directions: Test rational combination regimens with metabolic backbones and anti-inflammatory/antifibrotic add-ons; extend to hard clinical outcomes and durability; harmonize endpoints and reduce heterogeneity in future RCTs.
BACKGROUND: Metabolic-dysfunction-associated steatohepatitis has a rapidly expanding phase 2-3 drug pipeline, yet comparative evidence across mechanisms remains limited, and most trials are placebo controlled. METHODS: We performed a systematic review and frequentist network meta-analysis of phase 2-3 randomized trials in adults with non-cirrhotic disease. Primary endpoints were (1) resolution of steatohepatitis without worsening of fibrosis, (2) at least one-stage improvement in fibrosis without worsening of steatohepatitis (both biopsy based), and (3) at least a 30% relative reduction in liver fat measured by magnetic resonance imaging-derived proton density fat fraction. Interventions were compared across mechanistic groups and ranked using network estimates. FINDINGS: Sixty-four trials (12,787 participants) were included. Therapies targeting metabolic dysfunction and insulin sensitivity showed the most consistent benefits versus placebo (odds ratios 2.5-7.1) and the lowest failure rates across biopsy and imaging endpoints, whereas anti-inflammatory and anti-fibrotic agents showed more variable biopsy responses. Fibroblast growth factor 21 analogs and incretin-based multi-agonists ranked among the leading classes. Despite favorable relative effects, absolute non-response remained substantial: 35%-70% of treated participants did not meet prespecified biopsy endpoints, and biopsy placebo response rates were 11%-18%. CONCLUSIONS: By benchmarking cross-class performance in a predominantly placebo-anchored network, these findings support metabolic therapies as a rational foundation for combination regimens spanning complementary mechanisms and highlight the need for more durable approaches to achieve clinically meaningful biopsy outcomes. FUNDING: This work received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.